CN109715620B - 作为alk抑制剂的氨基嘧啶 - Google Patents

作为alk抑制剂的氨基嘧啶 Download PDF

Info

Publication number
CN109715620B
CN109715620B CN201780057518.0A CN201780057518A CN109715620B CN 109715620 B CN109715620 B CN 109715620B CN 201780057518 A CN201780057518 A CN 201780057518A CN 109715620 B CN109715620 B CN 109715620B
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780057518.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109715620A (zh
Inventor
王少萌
陈建勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Priority to CN202210533398.XA priority Critical patent/CN115043821B/zh
Publication of CN109715620A publication Critical patent/CN109715620A/zh
Application granted granted Critical
Publication of CN109715620B publication Critical patent/CN109715620B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780057518.0A 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶 Active CN109715620B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210533398.XA CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380818P 2016-08-29 2016-08-29
US62/380,818 2016-08-29
PCT/US2017/048845 WO2018044767A2 (en) 2016-08-29 2017-08-28 Aminopyrimidines as alk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210533398.XA Division CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Publications (2)

Publication Number Publication Date
CN109715620A CN109715620A (zh) 2019-05-03
CN109715620B true CN109715620B (zh) 2022-05-06

Family

ID=59846649

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780057518.0A Active CN109715620B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶
CN202210533398.XA Active CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210533398.XA Active CN115043821B (zh) 2016-08-29 2017-08-28 作为alk抑制剂的氨基嘧啶

Country Status (11)

Country Link
US (2) US10709705B2 (enExample)
EP (2) EP4001273A3 (enExample)
JP (2) JP7094566B2 (enExample)
KR (1) KR102530871B1 (enExample)
CN (2) CN109715620B (enExample)
AU (2) AU2017319135B2 (enExample)
IL (1) IL264638B (enExample)
MX (2) MX389265B (enExample)
NZ (1) NZ751713A (enExample)
SG (2) SG11201901251SA (enExample)
WO (1) WO2018044767A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3758705A4 (en) 2018-07-31 2021-08-04 Ascentage Pharma (Suzhou) Co., Ltd. CANCER TREATMENT METHOD USING A COMBINATION OF FAK / ALK / ROS1 INHIBITOR AND EGFR INHIBITOR
CN111171033B (zh) * 2018-11-09 2021-11-02 天津大学 一种嘧啶衍生物及其合成方法和应用
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
CN110143947B (zh) * 2019-05-29 2021-10-15 华东师范大学 一种色瑞替尼类似物的制备方法
CN113395968B (zh) * 2019-06-25 2024-03-01 苏州亚盛药业有限公司 用于治疗疾病的fak抑制剂和btk抑制剂的组合
CA3159348A1 (en) 2019-11-08 2021-05-14 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116261455B (zh) * 2020-09-25 2024-11-01 苏州亚盛药业有限公司 一种药物组合物及其在治疗癌症中的用途
US20240316051A1 (en) * 2021-04-19 2024-09-26 Ascentage Pharma (Suzhou) Co., Ltd. A pharmaceutical combination and use thereof
EP4446320A4 (en) * 2021-12-09 2025-11-26 Oncobix Co Ltd NEW HETEROCYCLIC SUBSTITUTION PYRIMIDINE DERIVATIVE WITH CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT
CN116332919B (zh) * 2022-03-30 2025-08-26 苏州亚盛药业有限公司 一种alk抑制剂化合物及其中间体的制备方法
TWI885708B (zh) * 2023-01-20 2025-06-01 大陸商蘇州亞盛藥業有限公司 Alk抑制劑或其鹽、溶劑合物的結晶形式及其製備方法和應用
WO2024193693A1 (zh) * 2023-03-22 2024-09-26 苏州亚盛药业有限公司 药物组合及其应用
WO2025232723A1 (en) * 2024-05-06 2025-11-13 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with focal adhesion kinase inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1852900A (zh) * 2003-09-18 2006-10-25 诺瓦提斯公司 可用于治疗增殖性病症的2,4－二(苯基氨基)嘧啶类
CN101921236A (zh) * 2003-03-14 2010-12-22 诺瓦提斯公司 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4-二(苯氨基)嘧啶
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR122019017579B8 (pt) 2003-08-15 2021-07-27 Novartis Ag 2,4-pirimidinadiaminas, seus usos, combinação e composição farmacêutica
RS52545B (sr) * 2004-04-07 2013-04-30 Novartis Ag Inhibitori protein apoptoze (iap)
KR101364277B1 (ko) 2006-12-08 2014-02-21 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
KR101238585B1 (ko) 2008-04-07 2013-02-28 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
MX2013004086A (es) 2010-10-14 2013-07-05 Ariad Pharma Inc Metodos para inhibir proliferacion celular en cancers accionados por egfr.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921236A (zh) * 2003-03-14 2010-12-22 诺瓦提斯公司 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4-二(苯氨基)嘧啶
CN1852900A (zh) * 2003-09-18 2006-10-25 诺瓦提斯公司 可用于治疗增殖性病症的2,4－二(苯基氨基)嘧啶类
WO2012106540A1 (en) * 2011-02-02 2012-08-09 Irm Llc Methods of using alk inhibitors
WO2015081813A1 (zh) * 2013-12-03 2015-06-11 上海翰森生物医药科技有限公司 具有alk抑制活性的化合物及其制备与用途
WO2015130014A1 (ko) * 2014-02-28 2015-09-03 한국화학연구원 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물

Also Published As

Publication number Publication date
AU2017319135B2 (en) 2021-03-18
SG10201914030UA (en) 2020-03-30
EP3504203B1 (en) 2022-09-28
CN115043821B (zh) 2024-08-06
KR102530871B1 (ko) 2023-05-09
AU2017319135A1 (en) 2019-04-04
US10709705B2 (en) 2020-07-14
JP7094566B2 (ja) 2022-07-04
CN109715620A (zh) 2019-05-03
BR112019003897A2 (pt) 2019-05-21
US20190175595A1 (en) 2019-06-13
EP4001273A3 (en) 2022-08-24
MX389265B (es) 2025-03-20
WO2018044767A3 (en) 2018-04-12
US11110090B2 (en) 2021-09-07
NZ751713A (en) 2022-07-01
WO2018044767A2 (en) 2018-03-08
CA3033223A1 (en) 2018-03-08
SG11201901251SA (en) 2019-03-28
JP2022120151A (ja) 2022-08-17
MX2019002393A (es) 2019-07-08
US20200330464A1 (en) 2020-10-22
MX2022000376A (es) 2022-02-10
EP4001273A2 (en) 2022-05-25
CN115043821A (zh) 2022-09-13
EP3504203A2 (en) 2019-07-03
AU2021203098B2 (en) 2023-05-25
IL264638B (en) 2021-08-31
JP2019528307A (ja) 2019-10-10
KR20190039760A (ko) 2019-04-15
AU2021203098A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
CN109715620B (zh) 作为alk抑制剂的氨基嘧啶
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
CN110294750A (zh) 作为alk抑制剂的5,6-二氢-11h-吲哚并[2,3-b]喹啉-11-酮化合物
CN110636843A (zh) 作为共价多发性内分泌腺瘤蛋白抑制剂的哌啶
KR20210072043A (ko) 소분자 mdm 2 단백질 분해제
CN111936465A (zh) 作为共价menin抑制剂的哌啶化合物
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
AU2017363161B2 (en) 5,6-dihydro-11H-indolo[2,3-b]quinolin-11-ones as ALK inhibitors
HK40077976A (en) Aminopyrimidines as alk inhibitors
HK40007649B (en) Aminopyrimidines as alk inhibitors
HK40007649A (en) Aminopyrimidines as alk inhibitors
HK40077976B (zh) 作为alk抑制剂的氨基嘧啶
HK40013399A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-ones as alk inhibitors
CA3033223C (en) Aminopyrimidines as alk inhibitors
HK40012150A (en) 5,6-dihydro-11h-indolo[2,3-b]quinolin-11-one compounds as alk inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
BR112019003897B1 (pt) Compostos de aminopirimidinas como inibidores de alk, composição farmacêutica bem como seus usos
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40022861A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40022861B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40007649

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant